Table 2. Rate of Primary Chemotherapy Completiona.
| Variable | No. (%) | P Value | |
|---|---|---|---|
| Primary Chemotherapy Completed (n = 408) | Primary Chemotherapy Not Completed (n = 162) | ||
| Age at diagnosis, y | |||
| ≤75 | 361 (76.2) | 113 (23.8) | <.001 |
| >75 | 47 (49.0) | 49 (51.0) | |
| Resectability status | |||
| Borderline resectable | 171 (73.4) | 62 (26.6) | .48 |
| Locally advanced | 237 (70.3) | 100 (29.7) | |
| Chemotherapy regimen | |||
| FOLFIRINOX | 214 (82.3) | 46 (17.7) | <.001 |
| Gemcitabine plus nab-paclitaxel | 81 (65.9) | 42 (34.1) | |
| GEMOX | 61 (76.3) | 19 (23.8) | |
| Gemcitabine | 52 (48.6) | 55 (51.4) | |
| MDACC Classificationb | |||
| A | 126 (76.4) | 39 (23.6) | .14 |
| B | 26 (72.2) | 10 (27.8) | |
| C | 19 (59.4) | 13 (40.6) | |
Abbreviations: FOLFIRINOX, fluorouracil, leucovorin, oxaliplatin, and irinotecan; GEMOX, gemcitabine and oxaliplatin; MDACC, MD Anderson Cancer Center; nab, nanoparticle albumin-bound.
a
Results are stratified by age, resectability at the time of diagnosis (according to National Comprehensive Cancer Network guidelines), type of primary chemotherapy, and MDACC classification.
b
Only for patients with borderline resectable pancreatic ductal adenocarcinoma.